Yazar "Trojano, M." için listeleme
-
Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis
Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Barnett, M. (Sage Publications Ltd, 2017)… -
Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide
Spelman, T.; Kalincik, T.; Trojano, M.; Grand'Maison, F.; Izquierdo, G.; Havrdova, E.; Butzkueven, H. (Sage Publications Ltd, 2016)… -
A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS
Spelman, T.; Havrdova, E.; Horakova, D.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)… -
Determinants of therapeutic lag in relapsing multiple sclerosis
Roos, I.; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Granella, F. (Sage Publications Ltd, 2019)… -
Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis
Le, M. V. H.; Malpas, C.; Sharmin, S.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Granella, F. (Sage Publications Ltd, 2018)… -
Early clinical predictors of severe MS
Malpas, C.; Sharmin, S.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Spitaleri, D. (Sage Publications Ltd, 2018)… -
The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis
Brown, J. W. L.; Coles, A.; Horakova, D.; Havrdova, E.; Trojano, M.; Izquierdo, G.; McCombe, P. (Sage Publications Ltd, 2017)… -
Evaluation of common criteria of progression of disability in a large observational cohort
Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Terzi, M. (Sage Publications Ltd, 2014)… -
Independent predictors of time to relapse after CIS in high-risk patients
Spelman, T.; Meyniel, C.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Grand'Maison, F.; Butzkueven, H. (Sage Publications Ltd, 2014)… -
Modifiers of the effectiveness of MS immunotherapies
Kalincik, T.; Malpas, C.; Sharmin, S.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Van Pesch, V. (Sage Publications Ltd, 2019)… -
of Therapeutic Lag in Relapsing Multiple Sclerosis
Roos, I.; Frascoli, F.; Horakova, D.; Havrdova, E. Kubala; Trojano, M.; Izquierdo, G.; Granella, F. (Sage Publications Ltd, 2020)… -
Risk of secondary progressive multiple sclerosis: a longitudinal study [Meeting Abstract]
Fambiatos, A.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Granella, F. (Sage Publications Ltd, 2017)… -
Therapeutic lag in relapsing multiple sclerosis
Roos, I.; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Granella, F. (Sage Publications Ltd, 2019)… -
Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis
Merkel, B.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Spitaleri, D. (Sage Publications Ltd, 2017)…